Cat. No.: HY-N2513

β-Boswellic acid

3 Cited Publications

Avis client

Based on 3 publication(s) in Google Scholar

β-Boswellic acid is isolated from the gum resin of Boswellia serrata with anticancer, antioxidant activity, anti-inflammatory activity and anti-arthritic pain.β-Boswellic acid is an orally active nonreducing-type inhibitor of the 5-lipoxygenase (5-LO) product formation either interacting directly with the 5-LO or blocking its translocation. β-Boswellic acid inhibits the synthesis of DNA, RNA and protein in human leukemia HL-60 cells with IC₅₀ values ranging from 0.6 to 7.1 μM. β-Boswellic acid is promising for research of diabetes, inflammatory and arthritic diseases.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.89%
CAS No.: 631-69-6
Formule: C₃₀H₄₈O₃
Masse moléculaire:456.70

Stockage:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

β-Boswellic acid Chemical Structure

CAS No.: 631-69-6

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (3)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

5-LO

Voir tous les produits spécifiques à Isoform Lipoxygenase :

Voir tous les produits spécifiques à Isoform DNA/RNA Synthesis :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	5 μM Compound: 1	Inhibition of microsomal PGES1 isolated from IL-1beta-stimulated human A549 cells preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis Inhibition of microsomal PGES1 isolated from IL-1beta-stimulated human A549 cells preincubated for 15 mins followed by substrate addition measured after 1 min by RP-HPLC analysis	[PMID: 24844534]
HeLa	IC₅₀	35 μM Compound: 1, BA	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 21334793]
HL-60	IC₅₀	15 μM Compound: 1, BA	Anticancer activity against human HL60 cells after 48 hrs by MTT assay Anticancer activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 22123322]
HL-60	IC₅₀	24 μM Compound: 1, BA	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 21334793]
Sf21	IC₅₀	>40 μM Compound: 26	Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis	[PMID: 31774676]

In Vitro

β-Boswellic acid (0-34 μM, 120 min) inhibits DNA, RNA and protein synthesis of HL-60 cells in a dose-dependent manner^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

β-Boswellic acid (1-20 mg/kg, p.o., daily for 21 days) lowers the blood glucose level, reverses Streptozotocin (STZ) (HY-13753)-mediated bodyweight reduction and reduces the levels of TC, TGs, LDL cholesterol and the serum SGPT, SGOT, ALP and serum creatinine in STZ-induced diabetic rats^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

STZ-induced diabetic rats^[4]
Dosage:

1-20 mg/kg
Administration:

p.o., daily for 21 days
Result:

Produced a significant antihyperglycemic effect on the 5th day onward in STZ-induced diabetic rats and significantly lowered the blood glucose level.

Chemical Information

CAS No. 631-69-6
Appearance Solid
Masse moléculaire 456.70
Formule C₃₀H₄₈O₃
Color White to yellow
SMILES

C[C@]12[C@@](CC=C3[C@]2(CC[C@]4(C)[C@@]3([H])[C@H]([C@H](C)CC4)C)C)([H])[C@@]5([C@@]([C@](C)([C@H](O)CC5)C(O)=O)([H])CC1)C
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
- Plants
- other families
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (3)

All

Sort by:

Journal Impact Factor

Phytomedicine

Xihuang Pill ameliorates the immune microenvironment of TNBC by activation of AMPKα-ACC signaling-mediated lipid metabolic reprogramming. [Abstract]

2026 Jul 25:157:158311. PMID: 42172981
3 Biotech

Mitochondria-mediated pyroptosis: anti-glioblastoma mechanism of the frankincense-derived compound β-boswellic acid. [Abstract]

2026 Feb;16(2):73. PMID: 41550484
PLoS One

Assessing the efficacy of frankincense extract as a root canal irrigant against Enterococcus faecalis. [Abstract]

2025 Apr 9;20(4):e0321458. PMID: 40202962

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (218.96 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1896 mL

10.9481 mL

21.8962 mL

5 mM

0.4379 mL

2.1896 mL

4.3792 mL

10 mM

0.2190 mL

1.0948 mL

2.1896 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.47 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.47 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.47 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (277 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Safayhi H, et al. Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther. 1992 Jun;261(3):1143-6. [Content Brief]

[2]. Shao Y, et al. Inhibitory activity of boswellic acids from Boswellia serrata against human leukemia HL-60 cellsin culture. Planta Med. 1998 May;64(4):328-31 [Content Brief]

[3]. Huang MT, et al. Anti-tumor and anti-carcinogenic activities of triterpenoid, beta-boswellic acid. Biofactors. 2000;13(1-4):225-30. [Content Brief]

[4]. Khan A, et al. Anti-diabetic potential of β-boswellic acid and 11-keto-β-boswellic acid: Mechanistic insights from computational and biochemical approaches. Biomed Pharmacother. 2022 Mar;147:112669. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1896 mL	10.9481 mL	21.8962 mL	54.7405 mL
	5 mM	0.4379 mL	2.1896 mL	4.3792 mL	10.9481 mL
	10 mM	0.2190 mL	1.0948 mL	2.1896 mL	5.4741 mL
	15 mM	0.1460 mL	0.7299 mL	1.4597 mL	3.6494 mL
	20 mM	0.1095 mL	0.5474 mL	1.0948 mL	2.7370 mL
	25 mM	0.0876 mL	0.4379 mL	0.8758 mL	2.1896 mL
	30 mM	0.0730 mL	0.3649 mL	0.7299 mL	1.8247 mL
	40 mM	0.0547 mL	0.2737 mL	0.5474 mL	1.3685 mL
	50 mM	0.0438 mL	0.2190 mL	0.4379 mL	1.0948 mL
	60 mM	0.0365 mL	0.1825 mL	0.3649 mL	0.9123 mL
	80 mM	0.0274 mL	0.1369 mL	0.2737 mL	0.6843 mL
	100 mM	0.0219 mL	0.1095 mL	0.2190 mL	0.5474 mL

Keywords

β-Boswellic acid

3 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

β-Boswellic acid

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Anti-diabetic Compound Library

Lipid Compound Library

Ferroptosis Compound Library

Terpenoids Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Blood Cancer Compound Library

Lipid Metabolism Compound Library

Food-Sourced Compound Library

Anti-Cancer Natural Product Library

Protein-protein Interaction Inhibitor Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Fatty Acids Compound Library

Anti-Fibrosis Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) β-Boswellic acid

Voir tous les produits spécifiques à Isoform Lipoxygenase

Voir tous les produits spécifiques à Isoform DNA/RNA Synthesis

Activité biologique

Chemical Information

Publications (3)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

β-Boswellic acid Related Classifications

HY-N2513 Related Classifications